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De novo AML exhibits greater 
microenvironment dysregulation 
compared to AML with 
myelodysplasia-related changes
Matheus Rodrigues Lopes1,†, João Kleber Novais Pereira1, Paula de Melo Campos1, 
João Agostinho Machado-Neto1, Fabiola Traina1,2, Sara T. Olalla Saad1 & Patricia Favaro1,3
The interaction between the bone marrow microenvironment and malignant hematopoietic cells can 
result in the protection of leukemia cells from chemotherapy in both myelodysplastic syndromes (MDS) 
and acute myeloid leukemia (AML). We, herein, characterized the changes in cytokine expression and 
the function of mesenchymal stromal cells (MSC) in patients with MDS, AML with myelodysplasia-
related changes (MRC), a well-recognized clinical subtype of secondary AML, and de novo AML. We 
observed a significant inhibitory effect of MDS-MSC on T  lymphocyte proliferation and no significant 
differences in any of the cytokines tested. AML-MSC inhibited T-cell proliferation only at a very low 
MSC/T cell ratio. When compared to the control, AML- MRC derived MSC presented a significant 
increase in IL6 expression, whereas de novo AML MSC presented a significant increase in the expression 
levels of VEGFA, CXCL12, RPGE2, IDO, IL1β, IL6 and IL32, followed by a decrease in IL10 expression. 
Furthermore, data indicate that IL-32 regulates stromal cell proliferation, has a chemotactic potential 
and participates in stromal cell crosstalk with leukemia cells, which could result in chemoresistance. Our 
results suggest that the differences between AML-MRC and de novo AML also extend into the leukemic 
stem cell niche and that IL-32 can participate in the regulation of the bone marrow cytokine milieu.
Myelodysplastic syndromes (MDS) are heterogeneous clonal haematopoietic stem cell (HSC) disorders that incur 
an increased risk of evolution to acute myeloid leukemia (AML)1, a well-recognized clinical subtype of second-
ary AML with myelodysplasia-related changes (AML-MRC)2. The biological and prognostic differences between 
de novo and secondary AML have been extensively documented, such as the worse outcome of younger patients 
with secondary AML, compared with de novo AML3.
HSC self-renewal, differentiation and proliferation are regulated in local tissue microenvironments called 
niches. One of the main cellular components of the HSC niche are the mesenchymal stromal cells (MSC), which 
are important regulators of haematopoiesis, as well as of the immune system4,5. It is rational to assume that MSC, 
derived from patients with hematological malignancies, harbor some partial defects, either primary or secondary, 
due to their exposure to altered marrow components. Extensive data have already shown interactions between 
leukemic cells and their microenvironment, supporting the idea that defects in the HSC microenvironment may 
play a role either in MDS or in AML development6–9. For instance, interactions between MSC from the leukemic 
stem cell niche and malignant cells are critical components of resistance to many chemotherapy agents10–12.
One of the hallmarks of malignancy13, inflammation, has been recognized as an important factor in the 
pathogenesis of MDS and AML, and involves different molecular and cellular signaling pathways1,14–16. Thus, 
the continuous inflammatory state provided by the HSC leukemic niche can contribute to the initiation and 
progression of diseases. Interleukin (IL)-32 is a proinflammatory cytokine, expressed as several isoforms17,18, 
that is thought to contribute to the pathogenesis of infection19–21, autoimmune diseases21 and cancer22,23. IL-32 
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induces inflammatory cytokines such as TNF-α , IL-1β , IL-6, and chemokines through the NF-κ B and p38 MAPK 
signaling pathways17. Previous data support a role for IL-32 in the pathophysiology of clonal myeloid diseases24.
In this study, we characterized cytokine expression changes and the function of MSC from patients with MDS, 
AML-MRC and de novo AML, in comparison to healthy control (HC) MSC. Moreover, we studied the ability of 
IL-32 to promote cell proliferation, chemotaxis of leukocytes and chemoprotection towards cytarabine (AraC) in 
the microenvironment.
Results
Expansion and characterization of MSC. MSC were cultured to confluence until the fourth passage. All 
8 samples obtained from HC were successfully cultured, while only 71% of the samples obtained from MDS (22 of 
31), 70% from AML-MRC (7 of 10) and 71% from de novo AML (12 of 17) were able to proliferate. The mean time 
to reach 80% confluency of samples obtained from MDS and AML-MRC were similar to those of HC (15 ± 6.2; 
12.6 ± 6.1; 13.5 ± 2.4 days, respectively, p > 0.05).
De novo AML cells reached 80% confluency in 21.2 ± 8.2 days, which represents a significantly slower growth 
than that of HC and AML-MRC samples (p < 0.05). Confirming mesenchymal origin, all patient-derived MSC 
presented a typical profile, standardized by the International Society for Cellular Therapy25, and very simi-
lar to that of HC-MSC (Supplementary Table 2). Low levels of CD34 and CD31 were sometimes detected in 
the AML-MRC group, either due to leukemia cell or endothelial cell contamination26 or due to macrophage 
contamination27.
To assess the capacity and efficiency for self-renewal of the MSC, a colony-forming unit-fibroblast (CFU-F) 
assay was performed in some of our patient-derived cells (5 samples of MDS and 2 samples of AML). The MSC 
derived from MDS patients showed a median of 23.2 CFU-F (range: 16–37) per 103 cells. The samples from 
MSC-derived AML presented 28 and 8 CFU-F per 103 cells. These results indicate the self-renewal capacity of our 
MSC derived from patient bone marrow.
Immunomodulative capability. The immunomodulatory properties of MSC have been well charac-
terized28, including suppression of T cell-mediated immunity29. Herein, the ability of patient-derived MSC to 
inhibit T cell proliferation was analyzed by mixing different ratios of MSC and CFSE-labeled CD3+ cells, in 
the presence of PHA. We observed a significant inhibitory effect of MDS-MSC on CD3+ cell proliferation up 
to the ratio of 1:100 (p < 0.05), in a dose-dependent manner, similar to that of HC-MSC (Fig. 1). This result 
remained significant when MDS patients were classified into subgroups, according to the WHO 2008 classifica-
tion (data not shown). On the other hand, in contrast to HC-MSC, which presented normal inhibitory properties, 
AML-derived MSC were able to significantly inhibit T-cell proliferation at lower ratios. AML-MRC derived-MSC 
only inhibited proliferation at a ratio of 1:2 (p < 0.001), and the de novo AML MSC inhibited up to a ratio of 1:10 
(p < 0.01) (Fig. 1). Further studies are needed to address the key aspects of the reduction of AML-MSC-mediated 
immunosuppression.
Figure 1. Proliferation of CD3+ T cells in coculture with MSC. T cell proliferation assays were performed 
using CFSE-labeled CD3+ T cells activated with PHA and cocultured with MSC (white and shades of 
gray columns) from healthy donors, myelodysplastic syndromes (MDS), acute myeloid leukemia with 
myelodysplasia-related changes (AML-MRC) and de novo acute myeloid leukemia (de novo AML) patients, 
or without MSC (positive control; black column) for 4 days at MSC:T cell ratios of 1:2, 1:5, 1:10, 1:50 and 
1:100 as shown in the figure. Cell proliferation was determined by flow cytometry after gating the lymphocyte 
population on the forward and side scatter plot and measuring the percentage of CFSE positive T cells. 
Results are shown as mean ± SEM and the number of samples in each group is shown in the figure. ANOVA, 
Bonferroni’s post-tests; *p < 0.05, **p < 0.01, ***p < 0.001.
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Cytokine profile in MSC. We next characterized the mRNA expression of cytokines and other molecules 
in patient-derived MSC and compared these to the HC samples. No significant difference was detected in the 
MDS-derived MSC group (Fig. 2). AML-MRC-derived MSC showed a significant increase in IL6 expression 
(p = 0.02). However, de novo AML MSC presented a significant increase in expression levels of vascular endothe-
lial growth factor A (VEGFA), stromal cell-derived factor 1 (CXCL12), receptor of prostaglandin E2 (RPGE2), 
indoleamine 2,3-dioxygenase (IDO), IL6 and IL32 (all p < 0.05), followed by a decrease in IL10 expression 
(p = 0.009) when compared to the HC group. We also observed a significantly increased expression of VEGFA, 
CXCL12, RPGE2 and IL32 in de novo AML, when compared with AML-MRC-derived MSC (p < 0.05). There 
were no differences in the expressions of TGFβ1 and IL1β.
We also analyzed the expression of the four best characterized isoforms of IL32 in our cohort. De novo 
AML MSC presented a significant increase in the expression levels of IL32γ(p = 0.01), the IL-32 isoform with 
the highest biological activity30. There were no differences in the expressions of the IL32α, β and δ transcripts 
(Supplemental Figure S1).
Figure 2. Modulation of cytokines and molecules is mostly observed in the de novo AML group. qPCR 
analyses of mRNA expression of VEGFA (A), CXCL12 (B), TGFβ 1 (C), RPGE2 (D), IDO (E), IL10 (F), IL1β (G), 
IL6 (H) and IL32 (I) in bone marrow MSC obtained from HC, MDS, AML-MRC and de novo AML patients. 
The “y” axis represents the relative mRNA expression. Horizontal lines indicate medians. The number of 
samples in each group and p values are indicated in the graph. Mann Whitney test.
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Silencing of IL-32 by miRNA and HS5 cell proliferation. Several studies have demonstrated that IL-32 
plays a role in the inflammatory microenvironment and that there is a network between IL-32 and other cytokines 
such as IL-1β , IL-6, IL-10 and VEGF17,19,21,22,31–33. To investigate the relation between IL-32 and MSC, we used 
HS5, a cell line with a stromal phenotype and with the ability to secret several cytokines, including IL-6 and IL-1, 
and to support hematopoiesis34. Since inflammation triggers MSC activity35, we also performed our experiments 
upon stimulation with IFN-γ and TNF-α . HS5 cells were stably transduced with two lentiviral constructs encod-
ing miRNA targeting IL32 (miIL32#1 and miIL32#2) or with miControl. After polyclonal cell selection with 
Figure 3. Lentivirus-mediated miRNA efficiently silences IL-32 in HS5 cells and results in increasing of cell 
proliferation. Western blotting analyses of IL-32 expression for HS5 cells in the presence or not of TNF-α and 
IFN-γ (10 ng/mL) as indicated. The levels of IL-32 relative to actin were quantified. In the figures are reported the 
cropped gels/blots. All gels were run in the same experimental conditions (see material and methods for details). 
(Full-length blots are reported in Supplementary Figure S2). Results are shown relative to miControl cells, as 
mean ± SEM of three independent experiments. ANOVA, Bonferroni’s post-tests (**p < 0.01; ***p < 0.001).  
(C) Cell viability was determined by MTT assay after 48 hours of incubation of miIL32 (#1 and #2) and normalized 
by the corresponding miControl cells. Results are shown as mean ± SEM of four independent experiments; 
The MTT assay was performed in the presence or not of IFN-γ and TNF-α (10 ng/mL) as indicated. ANOVA, 
Bonferroni’s post-tests (*p < 0.05, **p < 0.01); (D) Ki-67 mean of fluorescence intensity (M.F.I.) was determined 
by flow cytrometry after incubation of miIL32 for 48 h and normalized by the corresponding miControl cells. 
The dotted line represents the mean of miControl cells. Results are shown as mean ± SEM of four independent 
experiments; **p < 0.01, Student t test.
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blasticidin, the efficiency of IL-32 silencing was analyzed by Western blotting. A significant reduction in IL-32 
protein levels was observed in both constructions of miIL32 HS5, compared with miControl cells under regular 
and inflammatory conditions (Fig. 3A and B).
IL-32 is reported to have hematopoietic growth factor properties36, while IL-32 silencing results in a reduction 
in endothelial cell proliferation37. To determine whether IL-32 silencing affects stromal cell proliferation and/or 
viability, MTT assays were performed. Unexpectedly, viability of miIL32 HS5 cells was significantly increased (by 
~40%) when compared with miControl cells, with or without pro-inflammatory stimulation (p < 0.05; Fig. 3C). 
Ki-67 analysis revealed that IL-32 silencing significantly increased cell proliferation (Fig. 3D).
Chemotactic activity of IL-32 on PBMCs. Cell migration is essential for the induction of an effective 
immune response. To test whether IL-32 has any effect on PBMC recruitment, transwell chemotaxis of PBMC 
was performed in coculture with miControl or miIL32 HS5 cells. The number and type of PBMC that migrated 
through the membrane were analyzed. There was a significant decrease in CD45+ cells migration, which mainly 
reflects the significant decrease in CD4+ migration, with or without proinflammatory stimulation (p < 0.05; 
Fig. 4).
Similar effects on cell function were observed after IL-32 silencing with both the miIL32 sequences, imply-
ing that these effects are the result of RNAi-mediated silencing of the IL-32 gene rather than off-target effects. 
Since miIL32#2 showed a slightly better efficiency, we chose to carry out the subsequent experiments with this 
sequence.
Chemoprotection to AraC conferred by miIL32 HS5 cells. We firstly evaluated whether IL-32 silenc-
ing could modify the chemoprotection to AraC-induced apoptosis, the most effective drug for the treatment of 
AML38, conferred by HS5 to U937 cells39. As observed in Fig. 5A, IL-32 silencing does not modify the resistance 
of U937 cells to AraC when they are in contact with HS5 (p < 0.001).
Next, we tested whether the supernatant of miIL32 HS5 cells could change the chemosensitivity of U937 cells 
to AraC, using a transwell system. In these conditions, we observed that HS5 cells still protect U937 from AraC 
cytotoxicity. However, noncontact with miIL32 HS5 was significantly more effective than the miControl in inhib-
iting AraC-induced apoptosis of U937 cells (p < 0.05; Fig. 5B and D). Interestingly, this effect was reverted by the 
addition of TNF-α (Fig. 5C and D).
Modulation of cytokines, chemokines, MAPK and NF-κB signaling by IL-32. We also measured, 
in serum-free supernatants from cell culture of miControl and miIL32, the levels of cytokines and chemokines, in 
order to assess whether IL-32 regulates their expression in the stromal cell. The major cytokines downmodulated 
by IL-32 are demonstrated in Fig. 6A and B.
The ability of IL-32 to activate the p38 mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B 
(NF-κ B) pathways has been previously reported17,40,41. Herein, we sought to examine the effect of IL-32 on MAPK 
and NF-κ B signaling in our stromal cell line model. We observed that IL-32 depletion (Fig. 6C) resulted in a decrease 
in phosphorylation of NF-κ B, IKKα , IKKβ , c-Jun N-terminal kinase (JNK) and p38 MAPK (Fig. 6C and D). 
Figure 4. miIL32 HS5 cells have a decreased chemotactic activity on CD4+ cells in an inflammatory 
environment. miIL32 and miControl HS5 cells were seeded in the lower chamber of transwell plates with or 
without the addition of IFN-γ and TNF-α for 24 h before adding PBMCs, which were allowed to migrate for 
5 h. Data represent mean ± SEM (4 independent experiments). ANOVA, Bonferroni’s post-tests (**p < 0.01; 
***p < 0.001).
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Furthermore, we analyzed the phosphorylation levels of NF-κ B in samples from patient-derived MSC and 
HC-derived MSC. In this small set of patient-derived cells, NF-κ B phosphorylation levels were higher in the 
AML-derived MSC, especially in de novo AML samples (Fig. 6E). This finding is worthy of further research.
Discussion
In this report, we characterized and compared MSC derived from patients with MDS, AML-MRC and de novo 
AML with these from healthy controls. Although MSC from patients exhibited a typical antigen expression pro-
file, as already described by others42, we observed a reduced immunosuppressive ability of AML-MSC when com-
pared to the control. There are few studies about the immunosuppressive ability of AML-derived MSC43, although 
studies about MDS-MSC immunosuppressive function have been controversial43–46. We found that MDS-MSC 
were capable of satisfactorily inhibiting T cell proliferation in vitro induced by PHA, even when we classified our 
cohort as low or high-risk MDS, according to the WHO 2008 classification2. Supporting this finding, we observed 
no significant difference in any cytokine or molecule studied in the MDS-MSC. In agreement with Klaus et al.44, 
our data suggest that MDS-derived MSC are not the main factor responsible for the aberrant T cell response, 
sometimes observed in MDS patients.
We also demonstrated a distinct cytokine profile between AML-MRC and de novo AML-derived MSC, sug-
gesting that the difference between these two AML subtypes also extends into the leukemic stem cell niche. 
AML-MRC is characterized by the persistence of the malignancy, alterations in the hematopoietic niche caused by 
prior MDS treatment, a higher frequency of molecular mutations and cytogenetic abnormalities47. We observed 
that, despite the impaired immunosuppressive ability of the AML-MRC-derived MSC, their cytokine profile is 
very similar to that of the control group. Conversely, de novo AML-derived MSC presented a significant increase 
in their expressions of VEGF and IL6, both of which are secreted by the leukemic blast in order to promote their 
survival and proliferation48–51. Recently, Kim et al.52 demonstrated that leukemia stem cells from de novo AML 
patients can induce extensive alterations in the mesenchymal niche, resulting in an altered expression of cross-
talk molecules, including CXCL12. Together with the lower IL10 expression53,54, and the higher expression of 
IDO55–57, CXCL1258–60 and RPGE261–63 observed in our de novo AML cohort, we suggest that at least at the begin-
ning of this disease, prior to any treatment, MSC provides a permissive niche for leukemogenesis rather than 
normal hematopoiesis. Marcondes et al.22 showed an increase in IL32 expression in the bone marrow stromal 
cells from 13 patients with MDS. Nevertheless, in our cohort of 22 MDS patients we could not see any statistical 
difference between the MDS and HC groups. These differences may due to either a lack of standardized culture 
for bone marrow MSC or the heterogeneity of MDS patients. Furthermore, in de novo AML-derived MSC, we 
observed a significantly higher expression level of IL32, which reflects the expression of the most active isoform, 
IL32γ. It has been shown that the over expression of IL-32γ in an animal model resulted in the inhibition of the 
Figure 5. More effective chemoprotection following coculture of U937 cells with miIL32 HS5 cells using 
transwell chambers. U937 cells were cultured in the presence or absence of miControl or miIL32 HS5 cells 
in two distinct conditions: (A) direct contact or (B and C) noncontact (using a tranwell system). Cells were 
allowed to grow for 96 h and AraC was added (1 μ M) for the last 18 h of experiment. (C) TNF-α was added 
(10 ng/mL) at the same time as AraC. Apoptosis was assessed by flow cytometry analysis of Annexin-V-APC/
PI–stained cells. Data represent means ± SEM (6 independent experiments). ANOVA, Bonferroni’s post-tests 
(*p < 0.05; **p < 0.01; ***p < 0.001). (D) Dot plots are representative of one experiment.
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Figure 6. IL-32 silencing down-modulates cytokines, MAPK and NF- κB signaling components in HS5 
cells. (A,B) The fold-change in cytokine concentration in miIL32 HS5 cell supernatant compared to miControl 
cell values is plotted, in the presence or not of IFN-γ and TNF-α (10 ng/mL) as indicated. Results are shown 
as mean ± SEM of 3 independent experiments. (C) HS5 cells transduced either with miIL32#1 or miIL32#2 
and miControl. Western blot for IL-32, p-NF-κ B, p-IKKβ , and p-IKKα ; (D) p-JNK and p-p38 MAPK. (E) 
Activation status of NF-κ B signaling in AML-MSC patients; western blot for p-NF-κ B in total protein of MSC 
cells. Gels were run under the same experimental conditions while images of western blots displayed in cropped 
format. Membranes were reprobed with antibodies against actin or total protein. Full-length blots/gels are 
presented in Supplementary Figure S3.
www.nature.com/scientificreports/
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cell proliferation of melanoma and colon tumors64. Our results suggest that the higher expression of IL32γ in de 
novo AML-derived MSC could contribute to the slower-growing cells generated from these patients samples, 
as observed in our study. Accordingly, our in vitro results show that IL-32 inhibition resulted in a significantly 
increased stromal cell proliferation, with our without proinflammatory stimulation. IL-32 may have pleiotropic 
effects on cell proliferation, as indicated by many other cellular functions65–70.
Son et al. demonstrated that endogenously-secreted IL-32γ may regulate a variety of immune responses via 
CCL5 expression from dendritic cells, including chemotaxis of activated T cells71. We observed that silencing 
of IL-32 resulted in lower concentrations of CCL5 in the supernatant of HS5 cells, which may explain the sig-
nificantly decreased migration of CD4+ cells when cocultured with HS5 miIL32 cells. Additionally, many other 
important inflammatory molecules, including VEGF, TNF-α , IFN-γ , and IL-6 were reduced in the supernatant 
of HS5 miIL32 cells.
Our study on AraC-mediated cytotoxicity has shown that coculture of HS5 miControl or miIL32 with U937 
cells in vitro resulted in the same levels of enhanced protection compared to U937 without HS5 cells. However, 
the coculture of HS5 miIL32 with U937 cells using transwell assays resulted in a significant protection from 
AraC-induced apoptosis when compared to the coculture with HS5 miControl. It has been described that HS5 
cells can secrete a soluble factor(s) that protect U937 from AraC induced apoptosis72. Herein, we showed that 
IL-32 has a role in stromal cell crosstalk with leukemia cells, and that TNF-α must be part of this network, at least 
in vitro, since the protection from AraC-induced apoptosis conferred by HS5 miIL32 was reversed upon the addi-
tion of TNF-α . In a recent studies, it was shown that IL-32α suppressed colon cancer development by promoting 
the death signaling of TNFR173, and that IL-32γ can induce TFN-α production in differentiated THP1 cell line74.
Proliferation, leukocyte chemotaxis and regulation of the apoptotic threshold depend on appropriate signals 
through a favorable cytokine milieu for their homing to the bone marrow75–78. Our results suggest that IL-32 
participates in the regulation of the bone marrow cytokine milieu, at least in part, through MAPK and NF-κ B 
signaling.
In conclusion, we have shown a distinct function and cytokine profiles in AML-MRC and de novo 
AML-derived MSC, including the expression of IL-32. We also demonstrate that IL-32 takes part in the chemore-
sistance induced by MSC.
Materials and Methods
Primary samples. For isolation and expansion of MSC, bone marrow cells were obtained from 8 healthy 
donors (healthy control; HC) and 22 MDS and 19 AML patients. For the T cell proliferation and chemotaxis 
assay, peripheral blood mononuclear cells (PBMC) from HC (n = 26) were obtained by Ficoll-Hypaque gradient 
separation. All HC and patients provided their informed written consent, and all experiments were performed in 
accordance with the ethical and care guidelines and were approved by the local ethics committee of the University 
of Campinas and was adherent to the Declaration of Helsinki. Patients were untreated at the time of sample 
collection. Patients’ characteristics are described in Supplementary Table 1. MDS patients were classified according 
to the WHO 2008 classification2. Acute promyelocytic leukaemia [APL or AML with t(15;17)(q22;q12)] was 
excluded from the de novo AML group.
Cell lines and chemical reagents. The human bone marrow stromal cell line, HS5, and the human acute 
myeloid leukemia cell line, U93779, were obtained from the American Type Culture Collection (Manassas, VA, 
USA). 293FT and HT1080 cells were acquired in 2012 from Invitrogen (Carlsbad, CA, USA). Cells were cultured 
in appropriated medium, according to the manufacturer’s instruction, containing 10% fetal bovine serum (FBS) 
and glutamine with penicillin/streptomycin and amphotericin B, and maintained at 37 °C, 5% CO2. Recombinant 
human TNF-α and IFN-γ were purchased from PeproTech (Rocky Hill, NJ, USA). Cytarabine (AraC) was 
obtained from Intas Pharmaceuticals (Ahmedabad, India) and prepared as a 10 mM stock solution.
Isolation and expansion of MSC from bone marrow. Mononuclear cells were isolated from bone 
marrow by density gradient centrifugation and seeded at a density of 106 cells/cm2. After 3–4 days of adhesion, 
non-adherent cells were removed. Cells were cultured at 37 °C, 5% CO2 in DMEM medium containing 1% peni-
cillin/streptomycin, 1% L-glutamine and 10% fetal bovine serum, as described previously80. After achieving 80% 
confluence, the cells were removed with trypsin and plated again at a concentration of 4 × 103 cells/cm2, for fur-
ther passages. We performed all analyses at the fourth passage.
Quantitative PCR (q-PCR). Total RNA was purified using the TRIzol Reagent (Invitrogen). The reverse 
transcription reaction was performed using RevertAid First Strand cDNA synthesis kit (MBI Fermentas, 
Amherst, NY, USA). Expression of mRNAs was detected by qPCR with the Maxima SYBR Green qPCR master 
mix (MBI Fermentas) using the ABI 7500 Sequence Detection System (PE Applied Biosystems, Foster City, CA, 
USA). HPRT was used as an endogenous control (sequences of all genes at Supplementary Table 3). The relative 
quantification value was calculated using the equation, 2−ΔΔCT 81.
Flow cytometry. Immunophenotyping of MSC was evaluated by flow cytometry (FACSCalibur, 
Becton-Dickinson, San Jose, CA, USA). Fluorochrome conjugated monoclonal antibodies, anti-CD45-FITC or 
-PercP, CD34-APC, CD73-PE, CD31-FITC27, HLADR-FITC, CD90-PeCy5, and CD105PE. The U937 leukemia 
cell line was also stained for the detection of apoptotic cells (Annexin-V-APC positive/propidium iodide (PI) 
negative populations) after coculture with HS5 cells. Analyses were performed using the FACSDiva software 
(version 4.0.1, Becton-Dickinson) or FlowJo software (Treestar, Inc., San Carlos, CA, USA).
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Fibroblastic colony-forming unit (CFU-F) assay. CFU-F assays were performed by plating 1 × 103 cells/
well in 6-well plates. The medium was changed on day 7. After 15 days of culture, adherent cells were washed 
twice with phosphate-buffered saline, and stained with 1% crystal-violet in methanol. CFU-F colonies were mac-
roscopically enumerated and clusters of more than 50 cells were considered as colonies.
T cell proliferation assay. CD3+ cells were purified from isolated PBMC, by magnetic separation of 
bead-bound cells (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). Purity of CD3+ cells was 90–95%, as 
assessed by flow cytometry. CFSE-labeled CD3+ cells were resuspended and added to wells (105 cells/well) con-
taining MSC at MSC/T cells ratios of 1:2, 1:5, 1:10, 1:50 and 1:100 in the presence of PHA (2,5 μ g/mL). Four days 
later the CFSE fluorescence intensity was analyzed by flow cytometry (Becton-Dickinson).
Preparation of lentiviral vectors. Lentiviral vectors, expressing microRNA (miRNA) and targeting 
human IL-32 or LacZ were prepared using the BLOCK-iT Pol II miR RNAi Expression Vector with EmGFP 
System (Invitrogen), following the manufacturer’s instructions. The target sequence used to silence LacZ 
was 5′ -AAATCGCTGATTTGTGTAGTC-3′ . Two distinct sequences to silence IL-32 were used; sequence 1 
(5′ -AGAGGGCTACCTGGAGACAGT-3′ ) and sequence 2 (5′ -GAGACAGTGGCGGCTTATTAT-3′ ). Viral con-
centrations were determined by in vitro transduction in HT1080 cells and using blasticidin selection.
Transduction of lentivirus. HS5 cells were transduced with lentivirus-mediated miRNA targeting LacZ 
(named miControl) or lentivirus-mediated miRNA targeting IL-32; miIL32#1 for sequence 1 and miIL32#2 for 
sequence 2. Briefly, HS5 cell lines were seeded onto six-well plates at 5 × 104 cells/well, grown overnight, and 
transduced with lentiviral vectors at a multiplicity of infection equal to 1 in a minimal volume of medium con-
taining 6 mg/mL of polybrene (Sigma-Aldrich, St. Louis, MO, USA). The transduced cells were selected for 15 
days using blasticidin (10 μ g/mL) before functional analyses.
Western blotting. Western blot analysis was performed as described previously82. Anti-IL-32 (sc-134446) 
and actin (sc-1616) antibodies were obtained from Santa Cruz Biotechnology. Anti-phospho-SAPK/JNK 
(Thr183/Tyr185; #9251), SAPK/JNK (9252), phospho-p38 MAPK (Thr180/Tyr182; 9211), p38 MAPK (8690), 
phospho-NF-κ B p65 (Ser468; 3039), NF-κ B p65 (4764), phospho-IKKα /β (Ser176/180; 2697), IKKα (2682) and 
IKKβ (8943) were obtained from Cell Signaling. Quantification of band intensity was performed by UN-SCAN-IT 
(Silk Scientific, Orem, UT, USA).
Cell viability of HS5 cells. Cell viability was measured by methylthiazoletetrazolium (MTT) assay. After 
16 h of serum starvation, cells were stimulated to reenter the cell cycle and to proliferate using DMEM supple-
mented with 10% FBS. Serum starvation was not toxic to the cells (evaluated by Trypan blue; data not shown). A 
total of 9 × 103 cells per well were plated in 96-well plates in DMEM 10% FBS in the absence or presence of proin-
flammatory cytokines (10 ng/mL TNF-α and 10 ng/mL IFN-γ ) for 48 h. In brief, 10 μ L of a 5 mg/mL solution of 
MTT was added to the wells and incubated at 37 °C for 4 h. The reaction was stopped using 100 μ L of 0.1 N HCl in 
anhydrous isopropanol. Cell viability was evaluated by measuring the absorbance at 570 nm, using an automated 
plate reader. All conditions were tested in six replicates.
Cell proliferation by Ki-67 staining. After 16 h of serum starvation, cells were stimulated to reenter the 
cell cycle and to proliferate using DMEM supplemented with 10% FBS, exposed or not to the proinflammatory 
environment (10 ng/mL TNF-α and 10 ng/mL IFN-γ ). Ki-67 staining was performed following the manufac-
turer’s instructions (Ki-67 APC clone B56; Becton-Dickinson) and the mean fluorescence intensity (M.F.I.) was 
obtained by flow cytometry (FACSCalibur, Becton Dickinson). An IgG isotype was used as a negative control for 
each condition. Ten thousand events were acquired for each sample.
Chemotaxis assay. We performed a coculture of miControl or miIL32 HS5 cells and PBMC using a tran-
swell culture system (8 μ M-pore size membrane, Corning, NY, USA). HS5 cells were seeded in the lower chamber 
in DMEM/0.3% BSA exposed or not to an inflammatory environment (10 ng/mL TNF-α and 10 ng/mL IFN-γ ). 
After 24 h, PBMC were seeded in the upper chamber (105 cells/well). After 5 h, migrated cells were analyzed; cells 
from the lower chamber were trypsinized, stained with anti-CD45, anti-CD14, anti-CD4, and anti-CD8 and 
analyzed by flow cytometry. Results were calculated as the percentage of the 100% migration value (input).
Chemosensitivity assay to AraC. U937 cells were cocultured with miControl or miIL32 HS5 cells in two 
distinct conditions: direct contact or noncontact (using a 0.4 μ m porous transwell insert that allows passage of sol-
uble growth factors). Cells were allowed to grow for 96 h and AraC (1 μ M) with or without TNF-α (10 ng/mL) was 
added in the last 18 h of experiment. Cells were collected and submitted to Annexin-V-APC/PI double staining 
for flow cytometry. U937 cells were distinguished from miControl or miIL32 HS5 cells by a gate in GFP-positive 
cells. The analysis was performed using FACSDiva software (version 4.0.1, Becton-Dickinson).
Bio-Plex human cytokine quantification assay. Culture supernatants from miControl and miIL32 HS5 
cells, exposed or not to the proinflammatory environment (10 ng/mL TNF-α and 10 ng/mL IFN-γ ), were assayed 
for several cytokines, chemokines and growth factors using a Bio-Plex human cytokine 27-plex and 21-plex panel 
assay (Bio-Rad, Hercules, CA, USA). Samples were tested according to the manufacturer’s instruction. Data were 
collected and analyzed using a Bio-Rad BioPlex 200 instrument equipped with Bio-Plex Manager software ver-
sion 6.0 (Bio-Rad Laboratory, Hercules, CA, USA).
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Statistical analysis. Statistical analysis was performed using GraphPad Prism 5 (GraphPad Software, San 
Diego, CA, USA). For comparisons, Mann-Whitney or Student t tests were used for measured factors with 2 
levels; ANOVA followed by post-hoc Bonferroni was used for measured factors with 3 or more levels. A p < 0.05 
was considered as statistically significant.
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